Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19229468 | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF | June 2025 | November 2025 | Allow | 6 | 1 | 0 | No | No |
| 18924707 | VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION | October 2024 | February 2025 | Allow | 4 | 1 | 0 | No | No |
| 18650019 | PHARMACEUTICAL COMPOSITIONS TARGETING IMMUNE-MEDIATED PROCESSES IN NEURODEGENERATIVE DISEASE | April 2024 | October 2025 | Allow | 17 | 1 | 1 | No | No |
| 18618991 | FORMULA OF NEUREGULIN PREPARATION | March 2024 | March 2026 | Abandon | 24 | 1 | 0 | No | No |
| 18444102 | METHODS FOR INHIBITING DIAZEPAM BINDING PROTEIN | February 2024 | February 2025 | Allow | 12 | 2 | 0 | No | No |
| 18396206 | FLT3L-BASED CHIMERIC PROTEINS | December 2023 | December 2025 | Abandon | 24 | 0 | 1 | No | No |
| 18534366 | USE OF THE EXTRACELLULAR DOMAIN OF TRANSFERRIN RECEPTOR 2 FOR THE DIAGNOSIS OF DISEASE | December 2023 | February 2026 | Abandon | 26 | 2 | 1 | No | No |
| 18504723 | METHODS OF TREATING AN EYE DISORDER | November 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18497432 | FOOD-ALLERGEN SPECIFIC ANTIBODY COMPOSITIONS | October 2023 | August 2024 | Allow | 10 | 1 | 1 | No | No |
| 18496472 | Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders | October 2023 | July 2024 | Allow | 8 | 1 | 0 | No | No |
| 18491682 | HUMAN CD163 ANTIBODIES AND USES THEREOF | October 2023 | October 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18376196 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18367444 | AN AQUEOUS PHARMACEUTICAL FORMULATION INCLUDING A VEGF RECEPTOR FUSION PROTEIN | September 2023 | September 2024 | Allow | 12 | 1 | 0 | No | No |
| 18465145 | NUCLEIC ACIDS ENCODING PEPTIDES THAT BLOCK BINDING OF a2d-1 TO GLUTAMATE RECEPTORS FOR TREATING DISEASES AND DISORDERS | September 2023 | August 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18446018 | METHODS OF EXOGENOUS DRUG ACTIVATION OF CHEMICAL-INDUCED SIGNALING COMPLEXES EXPRESSED IN ENGINEERED CELLS IN VITRO AND IN VIVO | August 2023 | March 2025 | Allow | 19 | 1 | 0 | No | No |
| 18353623 | COMPOSITION COMPRISING RECOMBINANT GPIBA RECEPTOR PROTEIN | July 2023 | August 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 18219336 | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF | July 2023 | March 2025 | Allow | 20 | 1 | 1 | No | No |
| 18344786 | VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION | June 2023 | November 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18341278 | CXCL10 BINDING PROTEINS AND USES THEREOF | June 2023 | April 2025 | Allow | 21 | 1 | 1 | No | No |
| 18339061 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | June 2023 | April 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18332068 | METHODS FOR REDUCING MIGRAINE FREQUENCY IN A SUBJECT IN NEED THEREOF | June 2023 | October 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18331901 | Antibodies Targeting Integrin Beta-2 | June 2023 | December 2025 | Allow | 30 | 0 | 0 | No | No |
| 18328960 | Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same | June 2023 | October 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18165614 | ANTI-PAR2 ANTIBODIES AND USES THEREOF | February 2023 | June 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 18055642 | VEGF/DLL4 BINDING AGENTS AND USES THEREOF | November 2022 | August 2024 | Abandon | 21 | 0 | 1 | No | No |
| 18048345 | COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIES | October 2022 | April 2024 | Allow | 17 | 1 | 0 | No | No |
| 17996120 | CCL24 INHIBITORS IN THE TREATMENT OF COVID-19 | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17958710 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS | October 2022 | June 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17955111 | ANTIBODIES BINDING SPECIFICALLY TO NT-PROBNP AND USE THEREOF | September 2022 | October 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17935261 | METHODS FOR WEIGHT REDUCTION | September 2022 | December 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17946921 | ANTIBODIES TO L-TYPE VOLTAGE GATED CHANNELS AND RELATED METHODS | September 2022 | April 2024 | Allow | 19 | 1 | 1 | Yes | No |
| 17929824 | REDUCING ECZEMA AREA AND SEVERITY INDEX (EASI) IN SUBJECTS WITH ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODY | September 2022 | February 2026 | Allow | 42 | 1 | 0 | No | No |
| 17822705 | COMBINATION TREATMENT FOR CANCER | August 2022 | February 2025 | Abandon | 30 | 1 | 1 | No | No |
| 17822701 | RADIOCONJUGATES TARGETING CD33 IN THE TREATMENT OF SARCOMAS | August 2022 | November 2025 | Allow | 38 | 1 | 1 | No | No |
| 17883434 | RADIOCONJUGATES TARGETING CD33 IN THE TREATMENT OF CANCERS | August 2022 | December 2025 | Allow | 40 | 1 | 2 | No | No |
| 17813016 | METHOD FOR TREATING OR ALLEVIATING ENDOMETRIOSIS WITH IL-33 ANTAGONIST | July 2022 | November 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17811642 | THERAPEUTIC ANTI-CD40 LIGAND ANTIBODIES | July 2022 | January 2026 | Allow | 42 | 1 | 1 | No | No |
| 17840557 | ANTIGEN ANALOGUE FOR CALIBRATION OF IMMUNOMETRIC DIAGNOSTIC ASSAYS | June 2022 | June 2024 | Allow | 24 | 2 | 0 | No | No |
| 17783528 | CXCL10 BINDING PROTEINS AND COMPOSITIONS THEREOF | June 2022 | March 2023 | Allow | 10 | 0 | 0 | Yes | No |
| 17830298 | LONG-ACTING VEGF INHIBITORS FOR INTRAOCULAR NEOVASCULARIZATION | June 2022 | September 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17663675 | ANTI-C5 ANTIBODY COMBINATIONS AND USES THEREOF | May 2022 | May 2024 | Allow | 24 | 1 | 0 | No | No |
| 17740744 | Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders | May 2022 | November 2022 | Allow | 6 | 1 | 0 | No | No |
| 17725608 | PEPTIDE MIMETICS OF DKK3b AND METHODS OF USE | April 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17724399 | METHODS OF TREATING COLORECTAL CANCER | April 2022 | September 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17803251 | Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof | April 2022 | January 2026 | Allow | 45 | 1 | 1 | No | No |
| 17695592 | ANTI-CTLA4 MONOCLONAL ANTIBODY OR ITS ANTIGEN BINDING FRAGMENTS, PHARMACEUTICAL COMPOSITIONS AND USES | March 2022 | June 2025 | Allow | 39 | 1 | 0 | No | No |
| 17684057 | METHODS AND COMPOSITIONS FOR INCREASING THE DOSE OF A CHEMOTHERAPEUTIC AGENT | March 2022 | February 2024 | Allow | 24 | 1 | 0 | No | No |
| 17633351 | INHIBITION OF METASTASIS DEVELOPMENT BY NANGPTL-4 | February 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17628056 | GLYPHOSATE BIOSENSOR | January 2022 | December 2025 | Allow | 47 | 2 | 0 | No | No |
| 17578147 | NEUREGULIN BASED METHODS FOR TREATING HEART FAILURE | January 2022 | June 2024 | Allow | 29 | 1 | 0 | No | No |
| 17576886 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | January 2022 | April 2024 | Allow | 27 | 1 | 0 | Yes | No |
| 17570248 | HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF | January 2022 | February 2024 | Allow | 25 | 1 | 0 | Yes | No |
| 17558451 | POLYPEPTIDE COMPOSITIONS AND KITS FOR TREATING HEART FAILURE WITH PRESERVED EJECTION FRACTION | December 2021 | June 2025 | Abandon | 42 | 3 | 0 | No | No |
| 17546801 | ANTI-IL12RB1 ANTIBODIES | December 2021 | December 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17596145 | CHIMERIC AUTOANTIBODY RECEPTOR (CAAR) THAT BINDS AUTOANTIBODIES TARGETING THE CENTRAL NERVOUS SYSTEM IN NEUROLOGICAL AUTOIMMUNE DISEASE | December 2021 | January 2026 | Allow | 49 | 1 | 1 | No | No |
| 17615474 | ACTRII-BINDING PROTEINS AND USES THEREOF | November 2021 | October 2025 | Allow | 46 | 1 | 1 | No | No |
| 17615000 | G12-SPECIFIC DESIGNER RECEPTOR EXCLUSIVELY ACTIVATED BY DESIGNER DRUGS | November 2021 | December 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17526929 | LONG-ACTING VEGF INHIBITORS FOR INTRAOCULAR NEOVASCULARIZATION | November 2021 | April 2022 | Allow | 5 | 1 | 0 | No | No |
| 17525169 | SOLUBLE LIPIDATED LIGAND AGENTS FOR TREATING EYE INFLAMMATION | November 2021 | March 2024 | Allow | 28 | 1 | 0 | No | No |
| 17510271 | EXTENDED RELEASE OF NEUREGULIN FOR TREATING HEART FAILURE | October 2021 | September 2024 | Allow | 35 | 1 | 1 | No | No |
| 17508759 | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF | October 2021 | July 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17604891 | Netrin G1 Polypeptides | October 2021 | January 2026 | Allow | 51 | 1 | 1 | Yes | No |
| 17604495 | SIGLEC-BASED CHIMERIC POLYPEPTIDES AND USES THEREOF | October 2021 | December 2025 | Allow | 50 | 2 | 1 | No | No |
| 17604711 | IPILIMUMAB VARIANTS WITH ENHANCED SPECIFICITY FOR BINDING AT LOW PH | October 2021 | July 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17601321 | ANTI-CD25 ANTIBODY AND APPLICATION THEREOF | October 2021 | March 2025 | Allow | 42 | 1 | 0 | No | No |
| 17492649 | AFLIBERCEPT FORMULATIONS AND USES THEREOF | October 2021 | February 2024 | Allow | 29 | 1 | 0 | No | No |
| 17599481 | METHODS OF REDUCING LARGE GRANULAR LYMPHOCYTE AND NATURAL KILLER CELL LEVELS | September 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17599454 | TESTIS DEVELOPMENT RELATED PROTEIN ANTIBODIES | September 2021 | July 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17485067 | Methods Of Treatment Of Keloid Using An Anti-VEGF Agent | September 2021 | December 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17442608 | COMBINATION OF ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND PARP INHIBITOR | September 2021 | January 2026 | Allow | 52 | 2 | 1 | Yes | No |
| 17441028 | ANTI-ALPHA BETA TCR BINDING POLYPEPTIDES WITH REDUCED FRAGMENTATION | September 2021 | March 2025 | Allow | 42 | 1 | 0 | No | No |
| 17438653 | PRAME BINDING MOLECULES AND USES THEREOF | September 2021 | September 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17472051 | NUCLEIC ACIDS ENCODING ANTI-TREM-1 ANTIBODIES | September 2021 | December 2023 | Allow | 27 | 1 | 0 | No | No |
| 17472302 | ANTI-TREM-1 ANTIBODIES AND USES THEREOF | September 2021 | September 2023 | Allow | 25 | 1 | 0 | No | No |
| 17435370 | STABILIZED EXTRACELLULAR DOMAIN OF CD19 | August 2021 | December 2025 | Allow | 51 | 2 | 1 | No | No |
| 17459556 | THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES | August 2021 | April 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17434247 | ANTI-CD6 ANTIBODY COMPOSITIONS AND METHODS FOR TREATING LUPUS | August 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17434340 | ANTI-TNFR2 ANTIBODIES AND USES THEREOF | August 2021 | July 2025 | Allow | 46 | 1 | 1 | No | No |
| 17408768 | NOVEL RECOMBINANT BI-FUNCTIONAL FUSION PROTEIN, PREPARATION METHOD THEREFOR AND USE THEREOF | August 2021 | March 2022 | Abandon | 7 | 1 | 1 | No | No |
| 17407111 | COMPOSITIONS FOR DISEASE TREATMENT | August 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17430396 | ANTI-PD-L1 ANTIBODY AND USE THEREOF | August 2021 | December 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17430705 | CD1A ANTIBODY-EXPRESSING CAR T-CELLS FOR THE TREATMENT OF CD1A-POSITIVE CANCER | August 2021 | September 2024 | Allow | 37 | 0 | 0 | No | No |
| 17399364 | MONOCLONAL ANTIBODY AGAINST SPIKE S1 PROTEIN OF SARS-CoV-2 AND USE THEREOFOF | August 2021 | October 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17399367 | MONOCLONAL ANTIBODIES AGAINST SARS-CoV-2 NUCLEOCAPSID PROTEIN AND USES THEREOF | August 2021 | October 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17397221 | TREATMENT OF HODGKIN LYMPHOMA USING AN ANTI-PD-1 ANTIBODY | August 2021 | January 2025 | Abandon | 41 | 3 | 0 | No | No |
| 17396235 | METHOD OF PROMOTING WOUND HEALING BY INHIBITING CCR3 | August 2021 | September 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17384070 | Methods for Treating Angiogenic Eye Disorders with High Doses of VEGF Receptor Fusion Proteins | July 2021 | August 2023 | Allow | 25 | 1 | 0 | No | No |
| 17424591 | HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION | July 2021 | June 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17379968 | ANTI-TL1A ANTIBODIES AND USES THEREOF | July 2021 | October 2025 | Allow | 51 | 1 | 1 | Yes | No |
| 17420251 | HIGHLY MODULAR BIEPITOPIC AND BISPECIFIC CAR-T CELLS FOR CANCER IMMUNOTHERAPY | July 2021 | July 2025 | Allow | 48 | 1 | 1 | No | No |
| 17417603 | CONFORMATIONAL EPITOPE OF HEPATITIS B SURFACE ANTIGEN AND ANTIBODY BINDING SPECIFICALLY THERETO | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17416958 | PHARMACEUTICAL COMBINATION OF ANTI CEACAM6 AND TIM3 ANTIBODIES | June 2021 | September 2024 | Allow | 39 | 1 | 0 | No | No |
| 17352892 | USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS | June 2021 | December 2021 | Allow | 6 | 1 | 0 | No | No |
| 17054131 | METHODS FOR PROGNOSIS AND MANAGEMENT OF DISEASE | June 2021 | May 2025 | Abandon | 54 | 1 | 1 | No | No |
| 17350958 | USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS | June 2021 | May 2023 | Allow | 23 | 1 | 0 | No | No |
| 17348438 | VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION | June 2021 | May 2023 | Allow | 23 | 1 | 0 | No | No |
| 17347317 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS | June 2021 | June 2023 | Allow | 24 | 1 | 0 | Yes | No |
| 17298414 | CD40 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | May 2021 | December 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17330462 | PROTEINS COMPRISING CD3 ANTIGEN BINDING DOMAINS AND USES THEREOF | May 2021 | June 2025 | Allow | 49 | 3 | 1 | No | No |
| 17327914 | NUCLEIC ACID MOLECULES ENCODING ACTIVIN RECEPTOR TYPE IIA VARIANTS | May 2021 | March 2023 | Allow | 22 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LOCKARD, JON MCCLELLAND.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LOCKARD, JON MCCLELLAND works in Art Unit 1647 and has examined 1,198 patent applications in our dataset. With an allowance rate of 67.4%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 29 months.
Examiner LOCKARD, JON MCCLELLAND's allowance rate of 67.4% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by LOCKARD, JON MCCLELLAND receive 1.23 office actions before reaching final disposition. This places the examiner in the 15% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by LOCKARD, JON MCCLELLAND is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +37.8% benefit to allowance rate for applications examined by LOCKARD, JON MCCLELLAND. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 36.9% of applications are subsequently allowed. This success rate is in the 84% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 65.6% of cases where such amendments are filed. This entry rate is in the 89% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 93.5% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 89.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 52.9% are granted (fully or in part). This grant rate is in the 53% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 10.1% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.7% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.